Fangda represented Shanghai Brattea Medical Technology Co., Ltd. (“Brattea”) in its series D investment. The transaction was closed in March 2024. Fangda team on this deal was led by partner Luo Ke, and the team members included Elaine Li and Joshua Tsui. Fangda assisted in the drafting and negotiation of transaction documents and the closing process. Brattea mainly engages in the R&D of medical devices in relation to nerve radiofrequency ablation, including Renal denervation (RDN) for hypertension.
Fangda assists Brattea in completing its high-value series-D financing
2024 / 04 / 24
READ MORE
2026 / 11 / 09
Fangda Wins Final Victory for Client in PRC Court Proceedings Spanning Four Years over Jurisdiction Challenge, in Parallel with 197 Singapore International Commercial Arbitration Cases
2026 / 11 / 06
Fangda Advises Qyuns Therapeutics on Exclusive License Agreement with Caldera Therapeutics for TL1A/IL-17 Bispecific Antibody Program
2026 / 11 / 05
Fangda Advises Hinova Pharmaceuticals on Exclusive License Agreement with Evommune for VAV1 Molecular Glue Degrader EVO570
2026 / 11 / 04
Fangda Advises Minghui Pharmaceutical on Exclusive License Agreement with ASKA for MHB018A in Japan
2026 / 10 / 13
Fangda Assists Biren Technology on its Second H-share Placement



